PF-Atlas › Clinical Trials › NCT02070744

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

VX-661 · Phase 2

Registry ID

NCT02070744

Phase

Phase 2

Status

Completed

Drug / intervention

VX-661

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2014-03

Enrollment

Locations

About this trial

The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation

View NCT02070744 on ClinicalTrials.gov →

Explore related

All VX-661 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02070744 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.